FIELD: medicine.
SUBSTANCE: present invention refers to medicine and pharmaceutics, namely to application of 2-ethyl-6-methyl-3-hydroxypyridine succinate as an adjuvant preparation in complex therapy of diseases caused by beta-coronaviruses.
EFFECT: present invention provides higher effectiveness of complex therapy of coronavirus infection and reduced duration of treating the disease.
1 cl, 3 ex, 19 tbl, 1 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT OF NEW CORONAVIRUS INFECTION | 2022 |
|
RU2790939C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
| METHOD FOR PREDICTING THE OCCURRENCE OF ACUTE KIDNEY INJURY IN COVID-19-ASSOCIATED PNEUMONIA BASED ON THE LEVEL OF s-CysC | 2022 |
|
RU2788298C2 |
| METHOD FOR PREDICTING THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795093C1 |
| TECHNOLOGY OF REHABILITATION-PREVENTIVE NUTRITIONAL SUPPORT IN CORONAVIRUS INFECTION | 2020 |
|
RU2735723C1 |
| METHOD FOR RAPID DIAGNOSIS OF THE SEVERITY OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2789426C1 |
| METHOD FOR PREDICTING THE RISK OF HOSPITAL MORTALITY IN PATIENTS WITH A NEW CORONAVIRUS INFECTION COVID-19 | 2022 |
|
RU2780522C1 |
| METHOD FOR PREDICTING THE LETHAL OUTCOME IN PATIENTS WITH SEVERE CoVID-19 | 2021 |
|
RU2780748C1 |
| METHOD FOR PREDICTING OUTCOMES OF PNEUMONIA IN COVID-19 | 2022 |
|
RU2795095C1 |
| METHOD FOR DIAGNOSING MACROPHAGE ACTIVATION SYNDROME IN A NEW CORONAVIRUS INFECTION CAUSED BY THE SARS VIRUS - COV-2 | 2022 |
|
RU2778779C1 |
